A company submitted a Biologics License Application to the FDA.
2 reports, 2 independent
Updated Aug 18
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company submitted a Biologics License Application to the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
MannKind Corporation
biopharmaceutical company
Nothing else this week.
Related events
- MannKind Corporation met with the FDA regarding its plan file for approval.
- FDA provided guidance for HCW Biologics' IND application.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
Coverage
Newest first; wire copies grouped- Insider MonkeyMannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best h
- GlobeNewswireMannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update Conference call today at 9:00 am ET 2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $15